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Abstract We have previously shown that HMGA1 enhances
the transcriptional activity of promoters containing the estrogen
response element (ERE) and increases binding of the estrogen
receptor (ER) to ERE. Herein, we have assessed the transcrip-
tional activity and ERE-binding ability of deleted ER fragments
in absence or in presence of HMGA1. The HMGA1 protein
stimulated binding and transcriptional activity by a factor of
about 2-fold compared to the wild-type ER and both the N-
and C-terminal ER deleted domains, but had no e¡ect when
both domains were deleted. These data show that HMGA1
cooperates with either the N- or the C-terminal transcriptional
activation domain of the ER.
( 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The estrogen receptor (ER) is a member of a superfamily of
nuclear receptors (NR3A) [1] that have common structural
and functional domains. Each of these nuclear receptors is
comprised of six functional domains (A^F) that have been
evolutionarily conserved [2]. Two of the most highly con-
served regions are: the central DNA-binding domain
(DBD), domain C, and the C-terminal hormone-binding do-
main, domain E [3,4]. The DBD is responsible for the speci¢c
interaction of ER with the estrogen response element (ERE), a
palindrome consisting of GGTCA half-sites separated by a
linker sequence of 3 bp [5^7]. The hormone-binding domain
(E) directs the speci¢c interaction of the receptor with the
hormone. The other regions, the amino-terminal A/B domain,
the carboxyl-terminal F domain, and the centrally located
region D domain, display considerable variation in their ami-
no acid sequence. The ER contains of two transcriptional
activation domains (TADs), the A/B and the E domains
[8,9]. Numerous coregulatory proteins associate with these
two TADs and mediate the estrogen response. They could
be coactivators [10], corepressors [11,12] and accessory pro-
teins [13]. Therefore, transcription of steroid hormone-respon-
sive genes may be subject to the combined e¡ects of activators
and repressors that modulate the cellular response to the ER^
estrogen complex.
The HMG protein family constitutes a class of conserved
proteins involved in transcriptional regulation [14]. The
HMGA1 proteins (previously designated HMG I(Y)) [15]
are founding members of a class of non-histone nuclear pro-
teins known as architectural transcriptional factors [16^18].
The structural feature that distinguishes HMGA1 from other
HMG proteins is the presence of multiple DBDs called AT-
hooks that preferentially bind to the minor groove of AT-rich
regions of DNA [19^21]. The HMGA1 proteins recognize
their DNA substrate’s structure rather than nucleotide se-
quence, they have the ability to bend, unwind, and introduce
supercoils into DNA substrates and to speci¢cally interact
with other proteins, many of which are transcription factors
[18]. Because of this unusual characteristic, the HMGA1 pro-
tein is thought to play an important role in regulating the
expression of many di¡erent genes in vivo (reviewed in [14]).
The HMGA1 proteins are barely expressed in normal adult
tissues in both rodents and humans [22,23] but their expres-
sion is increased in tumors. It has been suggested that alter-
ations in the HMGA1 gene could play an important role in
the generation of benign or malignant tumors (reviewed in
[18,24^26]).
Recently we have demonstrated that HMGA1 enhances the
transcriptional activity of promoters containing ERE and in-
creases the binding of the ER to ERE [27]. It was unclear
which domain of ER mediated the HMGA1 e¡ect. The ma-
jority of the ERK-associated coregulatory proteins have been
isolated on the basis of their ability to interact with the ERK-
TAD (most commonly the LBD domain, domain E) rather
than with the DBD [28^31]. Since HMGA1 stimulated the
binding of ERK to DNA, it was of interest to determine which
ERK domain was required for this e¡ect. For this purpose, we
assessed the e¡ect of several ERK deleted fragments. The abil-
ity of HMGA1 to modulate ERE-mediated transcriptional
activity and ER binding to DNA was examined. Our binding
and transcriptional results are consistent; they showed that
HMGA1 requires the A/B and/or the E domains to increase
binding of ER and to enhance transcriptional activity of pro-
moters containing ERE.
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2. Materials and methods
2.1. Materials
All reagents were of molecular biology grade and were purchased
from Gibco. Oligonucleotides were purchased from Genset SA (Paris,
France). Recombinant ER was purchased from PanVera Corporation
(Madison, WI, USA). Antibodies directed against the N-terminal do-
main (SC-7207) or the C-terminal domain (SC-542) were purchased
from Dako (France). The human recombinant HMGA1 protein used
in these studies (speci¢cally the HMGA1a isoform) was produced and
puri¢ed by high performance liquid chromatography (HPLC)
(s 90%) as previously described [32]. For the reasons noted above,
in this report, the HMGA1a recombinant protein is referred to simply
as HMGA1. Transcription and translation coupled reticulocyte lysate
system (TNT) was purchased from Promega. 32P-radiolabeled nucleo-
tides were from Amersham Pharmacia Biotechnology (France).
[3H]acetyl coenzyme A and Econo£uor are NEN products (France).
2.2. Cell culture
The COS-7 and the HUH7 cells were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) with phenol red and supple-
mented with 10% fetal calf serum, 100 U/ml penicillin, 100 Wg/ml
streptomycin and 0.5 Wg/ml fungizone. 48 h before the experiments,
the medium was removed and replaced by DMEM without phenol red
supplemented with 10% charcoal-treated calf serum (complete
DMEM medium without phenol red).
2.3. Plasmids
Expression vectors for human wild-type ER (HE0) and ER deleted
fragments (HE15, HE19 and HE70) were previously described [33,34].
HE0 and HE19 have been previously subcloned into the EcoR1 site of
the pSG5 plasmid and HE15 and HE70 into the EcoR1 site of
BSM13+. For the sake of homogeneity, we subcloned HE15 and
HE70 into the EcoR1 site of the pSG5-Stratagene plasmid. The
ERE element was cloned into the HindIII site of the tk-CAT plasmid
(gift from Dr. C. Forest, Meudon, France) as previously described
[35]. The pRc-CMV-HMGA1 expression vector was generated by
subcloning the full-length human HMGA1a cDNA [36] into the
pRc-CMV eukaryotic plasmid expression vector (Invitrogen).
2.4. Cell extract preparation
COS-7 cells were transfected with HE0, HE15, HE19 and HE70 as
described by Massaad et al. [35]. For constructs containing the LBD
(HE0 and HE19), transfection was performed with complete DMEM
medium without phenol red. 48 h later and 1 h prior to harvesting,
estradiol (1037 M) was added to the cells.
Whole cell extracts was prepared by freezing cells at 380‡C, thaw-
ing them on ice and centrifuging at 10 000Ug for 15 min at 4‡C. The
supernatant was conserved at 380‡C.
HE70 was prepared using a transcription and translation coupled
reticulocyte lysate system (TNT, Promega). Brie£y, 4 Wg of pSG5-
HE70 was incubated with the TNT lysate, T7 RNA polymerase, an
amino acid mixture (1 mM), and a ribonuclease inhibitor (40 UI). The
reaction was incubated for 2 h at 30‡C.
2.5. Veri¢cation of plasmid expression
In order to verify the expression of HE0, HE15, HE19 and HE70,
‘Western blot’ analysis was performed in whole cell extract. Proteins
(50 and 100 Wg) and 200 ng of the human recombinant ER protein
(PanVera) were separated on 12% sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) gels. To each sample,
Laemmli bu¡er was added and then boiled for 2 min. Resolved pro-
tein was electrotransferred to nitrocellulose sheets, which were probed
with (i) the human polyclonal ERK antibody directed against the
amino acids 2^185, and (ii) the mouse polyclonal ERK antibody di-
rected against a peptide mapping at the carboxyl-terminus. The de-
tection was carried out using a peroxidase-conjugated anti-rabbit anti-
body. Immunoreactive bands were visualized using the enhanced
chemiluminescence detection system according to the manufacturer’s
instructions (Amersham Corp.).
The HE70 translated proteins were loaded onto 15% SDS^PAGE
gels, then gels were ¢xed (50% methanol, 10% glacial acetic acid) and
dried. Bands were visualized by autoradiography.
2.6. Preparation of competitors and radiolabeled probes
The ERE and the binding site for HMGA1 (the distal negative
regulatory element (DNRE)) sequences were synthesized and used
as probes for this study (Table 1). Probes were obtained by annealing
the coding and non-coding strands. The duplex molecules were la-
beled by the Klenow fragment of DNA polymerase I in the presence
of [K-32P]deoxycytidine triphosphate (dCTP) (s 3000 Ci/mmol; 1 Ci =
37 GBq).
2.7. Electrophoretic mobility shift assay (EMSA)
Binding reactions were carried out as described by Massade et al.
[27]. To evaluate the binding of the recombinant HMGA1 protein to
DNRE, and in order to verify that the HMGA1 protein was func-
tional, increasing concentrations of HMGA1 were mixed with the
binding reaction mix and with 0.1 ng of the DNRE probe.
The speci¢city of ERE binding to the HE0, HE15, HE19, HE70
proteins and the e¡ect of HMGA1 on them was determined in the
same EMSA.
The speci¢city of binding was assessed by competitive EMSA. Cell
extracts of HE19, HE15, HE70 were incubated with the binding re-
action mix and a 10-, 30- and 100-fold excess of homologous com-
petitors ERE.
The e¡ect of HMGA1 on ERE binding by the ER and its deleted
fragments was evaluated by adding increasing concentrations of
HMGA1 protein (20, 30 and 40 ng) to 90 ng of the ER recombinant
protein or to 10 Wl of whole extracts prepared with HE0, HE15, HE19
or HE70. ERE-containing complexes were quanti¢ed by PhosphoIm-
ager (Image Quant Software). The results were expressed as percent of
control (which represents the sample that was not incubated with the
HMGA1 protein).
2.8. Transfection experiments and CAT assay
They were performed by the calcium phosphate coprecipitation
technique in HUH7 cells, a di¡erentiated human liver cell line that
did not express the ER and expressed the HMGA1 protein at low
level. For each condition, the experiment was run in duplicate. The
CAT activity was determined using the two-phase assay described by
Massaad et al. [35]. Results were expressed in transcriptional activity
(%)= [CAT activity (dpm) elicited by each sampleU100]/[CAT activ-
ity (dpm) elicited by the ERE-tk-CAT plasmid]. Mann^Whitney
U-test was used to compare the mean of transcriptional activity be-
tween the transfected cells with the HMGA1 expression vector and
those transfected with the empty vector. All calculations were carried
out using Sigma Stat Software. The level accepted as signi¢cant was
P6 0.05.
3. Results
3.1. Expression of ER and its deleted domain
Fig. 1A describes the constructs used. HE0 represents the
wild-type (595 amino acids), in HE19 the A/B domains were
truncated (1^178 amino acids), HE15 lacks both E and F
domains (285^595 amino acids) and in HE70 the A/B domain
Table 1
Nucleotides sequences of the probes
Element Sequence
ERE consensus 5P-gaaAGGTCATGGTGACCTac-3P (strand I)
3P-cttTCCAGTACCACTGGAtggcgg-5P (strand II)
DNRE 5P-cagATTTAAGTCTAATTTAAAGTcgt-3P (strand I)
3P-gtcTAAATTCAGATTAAATTTCAgca-5P (strand II)
Unrelated nucleotides are shown in lowercase.
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was partially deleted (1^83 amino acids) as were both E and F
domains (282^595 amino acids), it encodes amino acids 83^
282.
Transient transfection was performed in COS-7 cell line for
all constructs and ‘Western blot’ analysis was performed for
each preparation (n=4), using an ERK antibody directed
against either the N-terminal part of the ERK protein, amino
acids 2^185 (Fig. 1B, lanes 2^6) or a peptide located at the
carboxy-terminal part (Fig. 1B, lanes 7, 8). The recombinant
ERK protein was used as a control (lane 4). As shown in Fig.
1B the antibody directed against the N-terminal part of the
protein recognizes the wild-type (HE0), the recombinant pro-
teins as well as the C-terminal truncated protein (HE15). After
stripping the membrane of the N-terminal antibody, the ERK
antibody directed against the carboxy-terminal part of the
protein was used. This antibody recognized the wild-type
(HE0) and the N-terminal truncated protein (HE19).
HE70 was prepared both in the COS-7 cell line and by in
vitro transcription and translation using the TNT kit (Prom-
ega). 35S-labeled HE70 produced in vitro was analyzed by
SDS^PAGE and autoradiography because no antibody
against the DBD is available. As shown in Fig. 1C, the
HE70 protein was produced in lysates programmed with plas-
mid PSG5-HE70 (Fig. 1C, lane 3) but not when the empty
vector pSG5 was used (Fig. 1C, lane 2).
3.2. HMGA1 increases ER binding to ERE
Firstly we evaluated the binding of recombinant HMGA1
protein to its responsive element DNRE, by EMSA. As
shown in Fig. 2A a shifted complex was observed, its intensity
increased with the concentration of HMGA1 (Fig. 2A, lanes
2^5). However, when the ERE-containing oligonucleotides
were incubated with increasing concentrations of the
HMGA1 protein, no band shift was observed (data not
shown). Then, we tested the e¡ect of HMGA1 on the re-
combinant ER protein (Fig. 2B, lanes 1^4) and on the wild-
type protein HE0 expressed in COS-7 cells (Fig. 2B, lanes 5^
8). As expected, when both recombinant ER or wild-type HE0
and HMGA1 proteins were combined, an increase in the in-
tensity of the shifted band was observed (Fig. 2B, lanes 2^4
and 5^8). These results were quanti¢ed and con¢rmed using
several independent preparations (n=4). The complex formed
between HE0 and the ERE increased about 3-fold in presence
of HMGA1 (Fig. 2B, right panel).
3.3. HMGA1 increases binding of the N- and C-truncated
ER proteins to ERE
We established the speci¢city of binding of the truncated N-
and C-terminal ER proteins to the consensus ERE by com-
petition experiments. The ERE sequence was used as both a
probe and a competitor. As can be seen in Fig. 2C and D, the
Fig. 1. Expression of the ER truncated fragments. A: Structure of wild-type ER and truncated fragments. B: COS-7 cells were transfected as
described in Section 2 with 20 Wg of the ER expression vectors (pSG5-HE0, pSG5-HE19, pSG5-HE15). Western blot was performed with 50
Wg (lanes 2, 5, 7) and 100 Wg (lanes 3, 6, 8) of protein. Lane 1 represents the molecular weight marker and lane 4 contains 200 ng of the ER
recombinant protein commercialized by PanVera. The human polyclonal ERK antibody directed against the amino acids 2^185 was used. This
antibody recognize the wild-type (HE0) and the recombinant proteins at 59.5 kDa (lanes 2, 3, 4) as well as the N-terminal truncated protein
(HE15) at 28.4 kDa (lanes 5, 6). After stripping the membrane of human antibody, mouse polyclonal ERK antibody directed against a peptide
located at the carboxyl-terminus was used. This antibody recognized HE0 and the C-terminal truncated protein (HE19) at 41.7 kDa (lanes 7,
8). C: HE70 was prepared by in vitro transcription and translation using the TNT kit (Promega). 35S-labeled HE70 produced in vitro was ana-
lyzed by SDS^PAGE, after migration the gel was ¢xed and dried, then bands were visualized by autoradiography (lane 1, MWM; lane 2, the
empty vector pSG5; lane 3, HE70 protein was produced in lysates programmed with plasmid PSG5-HE70). The arrow indicates the molecular
weight of the HE70 translated fragment. This experiment was repeated four times for each preparation (n=4).
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binding of both HE15 and HE19 to ERE decreased in the
presence of an increasing amount of the homologous compet-
itor (10- to 100-fold) (Fig. 2C and D, lanes 2^4).
To identify the region(s) that ERK requires to interact with
HMGA1, we tested the ability of HMGA1 to activate the
binding of N- and C-truncated proteins to DNA. When
HMGA1 was combined with HE15 or HE19, an increase of
the band intensity was observed (Fig. 2C and D, lanes 6^8)
compared to the deleted ER alone (Fig. 2C and D, lane 5).
The ratio of bound radioactivity in the complexes HE15^ERE
and HE19^ERE increased by about 2- to 3-fold in presence of
HMGA1 (Fig. 2C, D, right panel). However, in contrast with
Fig. 2. HMGA1 increases binding of truncated ER containing A/B and E domain to ERE. A: In order to show a control of the HMGA1 pro-
tein, EMSA was performed using the response element of HMGA1 (DNRE) probe and increasing amounts of the human recombinant protein
HMGA1 (0, 10, 20, 30, 40 ng) (lanes 1^5). B: The puri¢ed human commercial recombinant ER (PanVera) (lanes 1^4) or the expressed HE0
protein in COS-7 cells (lanes 5^8) were incubated with 0.1 ng of the ERE probe in the absence (lanes 1 and 5) or the presence (lanes 2^4 and
lanes 6^8) of increasing amounts of puri¢ed human recombinant HMGA1 protein (20, 30 and 40 ng). C: On the same EMSA, we analyzed
the speci¢city of HE19 binding to ERE (lanes 1^4) and the e¡ect of HMGA1 on HE19 binding to ERE (lanes 5^8). Lanes 1 and 5 represent
the HE19 binding to ERE. The speci¢city of binding was assessed by competitive EMSA using increasing amounts of unlabeled ERE (10-, 30-,
100-fold excess) (lanes 2, 3, 4 respectively). The e¡ect of HMGA1 on the HE19 construct was determined by increasing amounts of the re-
combinant HMGA1 protein (20, 30, 40 ng) (lanes 6, 7, 8). D: The same experiment was performed with the C-terminal truncated protein
(HE15). E: EMSA was performed using 0.1 ng of the ERE probe and the truncated HE70 in the absence (lane 1) or in the presence of increas-
ing amounts of unlabeled ERE (10-, 30-, 100-fold excess) or with increasing amounts of the recombinant HMGA1 protein (20, 30, 40 ng)
(lanes 5, 6, 7 respectively). The HMGA1 e¡ect was quanti¢ed, the right-hand panels represent the quanti¢cation of the complexes by Phos-
phoImager. The percent of bound radioactivity in the ER (wild-type HE0 or truncated fragments HE15, HE19 and HE70)^ERE complexes
was calculated. For every fragment, results were expressed as percent of control (0 ng of HMGA1). The results are the mean S.D. of four inde-
pendent preparations with at least three assays for each preparation.
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HE0, binding increased predominantly at the highest
HMGA1 concentrations.
3.4. HMGA1 does not modify the binding of the HE70 protein
(N- and C-truncated domains) to ERE
The same experiment was performed with HE70, which
includes the DBD but in which both TADs were at least par-
tially deleted. When HE70 was incubated with the radiola-
beled ERE in presence of increasing concentrations of the
ERE oligonucleotide, a speci¢c competition was observed
(Fig. 2E, compare lanes 2^4 to lane 1). In contrast with
HE15 and HE19, HMGA1 did not increase the binding of
HE70 to ERE (Fig. 2E, compare lanes 5^7 to lane 1, and
right panel).
3.5. The ERK A/B and E domains are required for activation by
HMGA1
We have tested the functional properties of the ER trun-
cated fragments in presence of HMGA1. HUH7 cells were
cotransfected with the reporter ERE-tk-CAT vector, the ER
expression vectors (HE0, HE19, HE15) and increasing
amounts of the HMGA1 expression vector (Fig. 3A). E2 acti-
vated the transcription approximately 4-fold when the expres-
sion vector HE0 was transfected and 1.5-fold for HE19 (Fig.
3B). As expected, E2 was ine¡ective for both HE15 and HE70
(data not shown). When the expression vector HMGA1 was
cotransfected with these constructs, an enhancement of tran-
scriptional activation was observed in induced cells for both
HE0 and HE19, which elicited the same pattern of induction
of about 2-fold but the basal activity remained unchanged. In
contrast, HE15 displayed an increase in the basal activity of
about 2-fold when the HMGA1 expression vector was added
and HE70 showed a very weak transcriptional activity that
was not enhanced by HMGA1 (Fig. 3B).
4. Discussion
A number of studies reported that puri¢ed steroid hormone
Fig. 3. HMGA1 enhances transcriptional activity of the ER in the HUH7 cell line. A: Structure of vectors. B: HUH7 cells were transfected
with 1 Wg of the ERE-tk-CAT plasmid, and 0.25 Wg of each expression vector (pSG5-HE0, pSG5-HE15, pSG5-HE19 or pSG5-HE70) with or
without 0.5 and 1 Wg of the expression vectors pRc-CMV-HMGA1. E2 was added at a ¢nal concentration of 1037 M. The total transfected
DNA amount was kept constant with the pRc-CMV plasmid. Results were expressed as percent of transcriptional activity= [CAT activity elic-
ited by each sampleU100]/[CAT activity elicited by the ERE-tk-CAT plasmid alone]. The results are the mean S.D. of four independent experi-
ments with for each point in duplicate. The U-Mann^Whitney test was used for statistical analysis, *P6 0.01.
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receptors bind poorly to their recognition sequences when
compared to receptors associated with other cellular proteins.
The addition of crude cellular extracts or other proteins re-
stores the ability of puri¢ed receptors to bind to DNA. This
suggests that nuclear receptors do not act alone but require
the participation of other cellular proteins to bind to DNA
[13,37^39]. In a previous study, we demonstrated that
HMGA1 could increase ex vivo the transcriptional activity
of ERE and in vitro the binding of ER to ERE without
altering the mobility of the DNA^protein complex in gel mo-
bility shift experiments. We also showed that this increase was
probably due to a protein^protein interaction [27]. In this
study, we investigated which of the ER domains was required
for the HMGA1 protein-stimulated ER binding to DNA and
transcriptional activity.
Wild-type ER, as well as the deleted receptors (HE0, HE15,
HE19, HE70), were able to bind to ERE. HMGA1 alone
could not bind to the ERE; however, addition of HMGA1
increased the binding of the complete ER protein (HE0) to the
ERE in a dose-dependent manner. Moreover, when we tested
the e¡ect of HMGA1 on the truncated ER fragments (HE15,
HE19) an increase of binding was observed in the presence of
HMGA1. The e¡ect of HMGA1 on HE0, HE19 and HE15
was similar at high concentrations. However, at lower
amounts of HMGA1, its e¡ect was more pronounced on
HE0 than these deleted receptors. This suggests cooperation
between the two domains to mediate the e¡ect of HMGA1.
Several studies reported that putative coregulators interact
in a hormone-dependent fashion with the C-terminal region of
ER, most commonly the LBD domain [9]. In the present
study, we have shown that HMGA1 enhanced the binding
to DNA of HE0, HE19 and HE15 even in the absence of
the LBD as in the case of HE15. This suggests that the e¡ect
of HMGA1 was not only dependent on the modi¢cation of
the LBD structure induced by ligand binding.
These binding observations correlated well with the func-
tional activity. In HUH7 cells, the ERE-containing promoter
was activated 2-fold by treatment with E2 for constructions
containing the LBD domain (HE0 and HE19). Under the
same condition, overexpression of HMGA1 signi¢cantly en-
hanced the induced transcriptional activity without a¡ecting
the basal activity of the reporter gene. This is due to the
presence of the LBD in both HE0 and HE19. Indeed, LBD-
containing ER is sequestered by various associated proteins
and is unlikely to bind to HMGA1 and activate target genes.
By interacting with this domain, E2 leads to the dissociation
of hsp90, hsp70 and other ER interacting proteins allowing its
binding to DNA. Under these conditions, HMGA1 can inter-
act with the ER. This hypothesis was supported by the fact
that the basal activity remains unchanged in presence of the
same concentrations of HMGA1. These observations suggest
that HMGA1 can activate ER binding to DNA only when it
is released from its inhibitory complex.
In contrast with HE0 and HE19, stimulation by HMGA1
of the transcriptional activity of the HE15 construct (amino
acids 1^182), which lacks the ligand-binding domain, is not
a¡ected by the E2 treatment. This mutant contains the DBD
responsible for speci¢c binding to ERE and the A/B region
which is a hormone-independent TAD. Importantly, this trun-
cated receptor is probably not associated with an inhibitory
complex.
The HE70 truncated fragment lacks the amino acids 1^82 in
the N-terminal part and the amino acids 283^594 in the C-ter-
minal part. HMGA1 was unable to modulate ex vivo the
transcriptional activity of ERE and in vitro the binding of
HE70 to ERE. The regions deleted in HE70 contain activa-
tion functions (AFs) 1 and 2 (AF-1 and AF-2); the region
between amino acids 41 and 150 is required for AF-1 activity
and that between the amino acids 530 and 553 is necessary for
the AF-2 activity. Previous deletion studies of ER showed
that the activity of AF-2 is ligand induced, whereas AF-1
itself exhibits constitutive activity [40]. Furthermore, a coac-
tivator-mediated functional synergism was reported between
AF-1 and AF-2 to stimulate transcription [41]. It is not clear
whether N- and C-terminal domains of ER were able to in-
teract directly with each other; indeed, a ‘bridging’ coactiva-
tor able to interact with both regions was hypothesized to be
required for an indirect interaction between the N- and C-ter-
mini [41]. Our working hypothesis is that HMGA1 can bind
to both the AF-1 and/or AF-2 and, by an as yet unclear
mechanism, increase the binding of the receptor to DNA. It
is possible that the presence of both AFs improves the e⁄-
ciency of HMGA1.
The role of HMGA1 could also be related to the impor-
tance of DNA topology in steroid receptor recognition of
hormone response elements. In fact, the ER binding to the
ERE results in a bend of the DNA toward the major groove.
DNA bending is thought to facilitate interactions between
components of the transcription complex bound to di¡erent
sites and to promote DNA looping to allow single proteins to
contact multiple DNA elements. HMGA1 participates in a
wide variety of nuclear processes ranging from chromosome
and chromatin mechanics to acting as an architectural tran-
scription factor that regulates the expression of numerous
genes in vivo [42^48]. A common feature of these processes
is the assembly of higher order nucleoprotein complexes. Since
endogenous hormone-responsive genes contain multiple tran-
scription factor-binding sites that are separated by varying
distances, HMGA1 could display a similar e¡ect on the higher
order nucleoprotein complexes formed on these genes in vivo.
In summary, we have shown that HMGA1 stimulates the
transcriptional activation by ER probably by stimulating its
binding to DNA. We also show that the e¡ect of HMGA1
requires both the N-terminal and the C-terminal AFs of the
ER. Given the high degree of conservation among the steroid
receptor superfamily members, it could be proposed that the
same domains in the presence of HMGA1 would also enhance
the binding of other steroid hormone receptors.
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